Key clinical point: A cognition survey of a large number of trial participants showed no signal of adverse effects from evolocumab treatment.
Major finding: Survey results showed cognitive compromise in 3.7% of patients on evolocumab and in 3.6% control patients on placebo.
Study details: Prespecified data collection from 22,655 patients enrolled in FOURIER, a multicenter, randomized trial.
Disclosures: FOURIER was sponsored by Amgen, the company that markets evolocumab (Repatha). Dr. Guigliano has received personal fees and research support from Amgen and from several other companies.
Gencer B et al. J Am Coll Cardiol. 2020 May 12;75:2283-93.